How do the two forms differ?

The supplied material identifies CJC-1295 as a modified synthetic GHRH(1-29) analogue. It distinguishes an albumin-binding DAC variant from a no-DAC form, also called Modified GRF 1-29; the latter is reported to have a much shorter action period.

What did the human study measure?

The cited human study material reports changes in GH and IGF-I after administration. It does not provide large, long-term human trials demonstrating muscle-gain or fat-loss outcomes.

Is CJC-1295 FDA approved?

Not according to the supplied record. It identifies CJC-1295 as not FDA approved and describes a discontinued Phase II investigational program. The dated category and PCAC statements in that record should be checked against official FDA materials.

What are the key evidence limits?

The provided material supports short-term pharmacodynamic findings, but leaves long-term safety and practical clinical benefit unresolved. Reported muscle-gain and fat-loss interests are not established outcomes in the supplied evidence.

Which safety issues are reported in the source?

The source lists injection-site reactions, flushing, headache, water retention and dizziness, with possible histamine release in sensitive people. It also flags theoretical concern where higher GH or IGF-I activity may be undesirable, including cancer contexts, and notes immunogenicity as a risk. These source-reported items do not establish their frequency or long-term incidence.

Growth Hormone Clinical Trials - human trials under way

Modified GRF (1-29)

Also known as: CJC-1295 without DAC, CJC-1295 No DAC, Tetrasubstituted GRF (1-29)

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

A GHRH analogue reported in albumin-binding DAC and shorter no-DAC forms.

Status

Clinical Trials

Evidence level: human studies

Typical dose

The community-reported amount appears in the dosing row.

Subcutaneous route

Researched for

The source lists growth hormone optimization, muscle gain, and fat loss as research interests; it does not establish those benefits.

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Not applicable - Emerging human evidence with important limitations

Use the tools

In plain language

Synthetic GHRH(1-29) analogue reported in DAC and no-DAC forms.
DAC is described as albumin-binding and longer-lived; no-DAC is also called Modified GRF 1-29.
Supplied human evidence concerns GH and IGF-I pharmacodynamics, not established body-composition outcomes.
The source says development by ConjuChem ended after Phase II and describes the compound as a research chemical rather than an approved drug.

How it's thought to work

CJC-1295 is described as a synthetic modification of GHRH(1-29). The supplied material says it activates GHRH receptors on pituitary somatotrophs, increasing pituitary GH release, with hepatic IGF-I production following the GH rise. Native GHRH is described as being degraded within minutes. In the DAC variant, a reactive moiety is reported to attach covalently to circulating albumin after injection, reducing breakdown. The no-DAC form, Modified GRF 1-29, lacks this attachment and is reported to act for about 30 minutes. The described pathway depends on residual pituitary capacity for GH production.

What the research shows

Where the research stands

Evidence reviewed for CJC-1295 separates pharmacokinetic findings from clinical outcomes. The DAC form is described as having a of roughly 6 to 8 days, whereas the non-DAC form is described as acting for about 30 minutes. In the 2006 randomized ascending-dose study, one injection was associated with GH elevation lasting at least 6 days and IGF-I elevation for 9 to 11 days; repeat dosing produced cumulative hormone effects. A mouse experiment reported restored growth with daily exposure. The material does not provide large, long-term human trials demonstrating fat loss or muscle gain. Development stopped after Phase II, and the reported trial death was attributed by the treating physician to pre-existing coronary disease, an attribution not independently confirmed.

What it shows

✓ Human studies

Emerging human evidence with important limitations

△ Limitations

Study protocols describe research and are not dosing recommendations.

Bottom line: The source characterizes the program as investigational and Phase II-discontinued. It reports Category 2 removal in September 2024 for PCAC review, a Category 1 reclassification expectation on April 15, 2026, and PCAC review on July 23–24, 2026; it says Category 2 remains pending a formal FDA rule. Not FDA Approved

Typical dosing

CommunityCommunity dataset

100 mcg

daily (no DAC) or 2 mg weekly (with DAC)

100 mcgfull range seen300 mcg

The source describes daily use for no-DAC and a longer-lived DAC form. It also mentions co-use with a GHRP such as Ipamorelin. This community report is informational rather than medical advice.

Research dosing

Study-specific protocolsHuman trials under way - protocols are study-specific

Doses observed in studies

CJC-1295 DAC: 1-2mg weekly

Research Literature - Observed in studies

Study protocols describe research and are not dosing recommendations.

Duration: 8-12 weeks
Administration: Subcutaneous injection

Timing & administration

Best time to take

Before bed

1-2 times per week

Food recommendation

Take on empty stomach

Why this timing?

For DAC, the source gives an approximately 8-day half-life, so it treats clock time as less material; it nevertheless associates evening use with natural GH patterns.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well-tolerated
Injection site reactions
Facial flushing
Headache
Water retention
Dizziness
Possible histamine release
IGF-I/GH-related concerns for people with cancer
Risk of immunogenicity

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Modified GRF (1‑29)

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Modified GRF (1-29)

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions